Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Myotonic Dystrophy
100%
Small Molecules
100%
RNA Transcripts
50%
Treatment Options
50%
New Leads
50%
Gain-of-function
50%
Muscleblind-like
50%
Muscular Dystrophy
50%
Adult-onset
50%
Model Scoring
50%
Most Common Form
50%
Sequester
50%
Mis-splicing
50%
3′-untranslated Region (3′-UTR)
50%
CTG Repeat Expansion
50%
Disease Progression
50%
Cardiac Function
50%
Phenotypic Improvement
50%
Triplet
50%
Genetic Origin
50%
Alternative Splicing
50%
Therapeutic Agents
50%
Sequestration
50%
Novel Therapeutics
50%
Spliced RNA
50%
Activity Level
50%
Pre-mRNA
50%
Normal Function
50%
Neuromuscular Disorders
50%
Toxic Agents
50%
Myotonic Dystrophy Protein Kinase
50%
Evidence-based Support
50%
Self-development
42%
Cell Culture Model
42%
Therapeutic Targeting
42%
Mouse Model
42%
Self-assembling
42%
Cellular Assay
42%
ADME-Tox
42%
Drosophila Model
42%
Drug-likeness
42%
Muscle Targeting
7%
Oligomeric
7%
Discrete Oligomers
7%
In Vivo Test
7%
Multivalent
7%
Medicine and Dentistry
Myotonic Dystrophy
85%
Disease Exacerbation
42%
Heart Function
42%
Cell Culture
42%
Untranslated Region
42%
Messenger RNA Precursor
42%
Absorption Distribution Metabolism Excretion
42%
Neuromuscular Disease
42%
Synapsin I
42%
Therapeutic Agent
42%
Myotonic Dystrophy Protein Kinase
42%
Alternative RNA Splicing
42%
Toxic Agent
42%
Muscular Dystrophy
42%
Treatment Option
42%
Genetics
42%
Biochemistry, Genetics and Molecular Biology
Small Molecule
100%
RNA
100%
Untranslated Region
32%
Synapsin I
32%
Heart Function
32%
Animal Model
32%
Myotonin-Protein Kinase
32%
Alternative Splicing
32%
Precursor mRNA
32%
Genetics
32%
Transcription
32%
Mouse Model
28%
Cell Culture
28%
Fruit Fly
28%